William Blair Biopharma investment banking group director Eason Hahm was quoted in sector publication Biopharma Dive, where she discussed companies in the industry looking to offload assets through liquidation and other means.
“Boards and investors [are] saying, ‘Look, I think I can make the decision better on where that capital would be best used, perhaps better than just rolling it into another company,’” Hahm said.